Summary
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on April 29, 2026, to report its financial and operating results for the first quarter ended March 31, 2026. The key details of these results are provided in a press release, which is incorporated by reference as Exhibit 99.1 to this filing. Investors should note that the information furnished under Item 2.02, including the press release, is not considered "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 unless expressly incorporated into a future SEC filing. Investors seeking specific financial performance metrics, revenue figures, pipeline updates, or forward-looking guidance for the first quarter of 2026 should refer directly to the press release filed as Exhibit 99.1.
Key Highlights
- 1Regeneron Pharmaceuticals, Inc. announced its Q1 2026 financial and operating results on April 29, 2026.
- 2The detailed results are contained within a press release furnished as Exhibit 99.1 to the 8-K filing.
- 3Investors should consult Exhibit 99.1 for specific performance data for the quarter ended March 31, 2026.
- 4The filing serves as notification of the release of Q1 2026 earnings information.
- 5Information furnished under Item 2.02 is not deemed 'filed' unless explicitly referenced in a subsequent filing.